GlassScriptPhysician profile
Michael John Brown
NPI 1164911541
$4,426.98
in general payments reported to CMS, 2019-2025
15 companies · $667 in 2025
The $667 reported for 2025 was more than what a typical Podiatrist provider received nationally (typical 2025 total: $260).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,705 · 2022: $304 · 2023: $526 · 2024: $225 · 2025: $667.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,417.54 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pinnacle, INC | $2,418.00 | 2021 | |
| Smith+Nephew, INC. | $660.41 | 2021-2025 | Stravix, Collagenase Santyl, Grafix Pl |
| Paragon 28, INC. | $313.30 | 2021-2025 | Portfolio, Mtp, Tenotac 2.0 |
| Stryker Corporation | $223.87 | 2022-2025 | Ortholoc 3di Crosscheck, Omega, Swanson |
| Treace Medical Concepts, INC. | $151.03 | 2022-2025 | |
| Kerecis Limited | $138.15 | 2025 | Kerecis Surgiclose, Kerecis Graftguide |
| Amgen INC. | $136.64 | 2025 | Krystexxa |
| Mimedx Group, INC. | $135.61 | 2025 | |
| Horizon Therapeutics Plc | $112.01 | 2021-2023 | Krystexxa |
| Depuy Synthes Sales INC. | $41.26 | 2021-2024 | Na |
| Organogenesis INC. | $23.31 | 2023 | Puraply |
| Osteomed LLC | $20.06 | 2021 | |
| Convatec INC. | $19.08 | 2023 | |
| Paratek Pharmaceuticals, INC. | $18.53 | 2025 | Nuzyra |
| Surgenex LLC | $15.72 | 2025 | Surmatrix, Pellograft, Renograft |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Brown listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.